Report Overview

The APAC Psoriasis Drugs market size stood at around USD $1.1 billion in 2019 and is projected to reach USD xx billion by 2028, exhibiting a CAGR of xx% during the forecast period

Psoriasis is a non-communicable inflammatory skin condition that alters the life cycle of skin cells by speeding up the growth of cells on the skin's surface. The rapid development of cells produces thick, silvery scales and makes the skin red, dry, flaky, and itchy. Currently, no permanent cure is available for the disease. However, preventative measures can be adopted to slow down skin cells' growth on the surface of the skin. Psoriasis can be treated either with pharmaceuticals or biopharmaceuticals therapies through the topical and systemic process



 

Market Drivers

The growth of the Psoriasis Drugs market is majorly driven by factors such as rising healthcare expenditure, the introduction of a novel and more efficient drug, and expected entry of late-stage products. The market's key restraints are the high cost involved in drug development, patent expiry of brand name drugs, and low efficacy of the product